11/20/2008 10:25:38 AM
STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: Karo Bio (STO:KARO) and Wyeth Pharmaceuticals have a drug discovery collaboration with the liver X receptor (LXR) as pharmaceutical target. LXR is a new member of the nuclear receptor protein family and the receptor plays important roles in cholesterol metabolism and inflammatory responses. The collaboration with Wyeth has primarily been focused on atherosclerosis but other clinical opportunities have also been explored. The continued collaboration will focus on drug discovery in the field of inflammatory diseases.
comments powered by